BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...

In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...

Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus ...

NEW YORK, April 17, 2026--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific ...

Dr. Sita Kugel’s team recently published two papers identifying a key biological signature that not only provides clinics a faster, cheaper way to tell pancreatic cancer subtypes apart, but reveals a ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, owing in part to the often late stage at which it is diagnosed. Biomarker development for HCC aims to improve ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...

Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers The metabolic subtypes robustly defined in ...